** Jefferies raises PT on Telix Pharmaceuticals TLX.AX to
A$13.30 from A$13.00 on ongoing U.S. sales growth of Illuccix
product
** The cancer-focused pharma co on Tuesday posted a
multi-fold jump in FY revenue to A$160.1 mln ($107.64 mln) from
last year's A$7.6 mln
** However, Telix logged a net loss after tax of A$104.1
mln, versus with a profit of A$80.5 mln due to investment to
scale-up commercial and clinical activities
** Jefferies says growth can continue and hikes FY23 U.S.
Illuccix gross margin sales
** Broker says emerging clinical practice in the United
States that includes multiple PET scans bodes well for TLX's
sales growth
** All of the six analysts rate stock "buy" or higher; their
median PT is A$9.29 - Refinitiv data
** YTD, Telix stock down ~4%
($1 = 1.4874 Australian dollars)
(Reporting by Savyata Mishra in Bengaluru)
((Savyata.Mishra@thomsonreuters.com))